Resmed Inc. Stock
Price
Target price
€221.30
€221.30
0.960%
2.1
0.960%
€243.86
06.06.25 / Tradegate
WKN: 895878 / Symbol: RMD / Name: ResMed / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Resmed Inc. Stock
Resmed Inc. gained 0.960% compared to yesterday.
We see a rather positive sentiment for Resmed Inc. with 18 Buy predictions and 1 Sell predictions.
As a result the target price of 243 € shows a slightly positive potential of 9.81% compared to the current price of 221.3 € for Resmed Inc..
Pros and Cons of Resmed Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Resmed Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Resmed Inc. | 0.960% | 2.691% | 4.043% | 13.896% | -0.450% | 12.232% | 54.755% |
| Veeva Systems A | -0.320% | 1.623% | 22.266% | 47.251% | 23.228% | 41.581% | 39.359% |
| Thermo Fisher Scientific Inc. | 1.340% | -0.550% | -1.426% | -33.800% | -29.378% | -32.157% | 12.416% |
| Waters Corp. | 1.300% | -1.465% | 3.791% | 9.561% | -12.992% | 1.326% | 72.849% |
Comments
ResMed Inc. (NYSE: RMD) had its price target lowered by analysts at UBS Group AG from $290.00 to $285.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed Inc. (NYSE: RMD) had its price target raised by analysts at JPMorgan Chase & Co. from $286.00 to $290.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
ResMed Inc. (NYSE: RMD) had its price target lowered by analysts at KeyCorp from $280.00 to $269.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RMD provided by MarketBeat
News
ResMed: Digital Health Drives Q2 Growth
ResMed (NYSE:RMD), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst
